Abstract. Angiotensin-converting enzyme-2 (ACE2) is the first human homologue of ACE to be described. ACE2 is a type I integral membrane protein which functions as a carboxypeptidase, cleaving a single hydrophobic/basic residue from the C-terminus of its substrates. ACE2 efficiently hydrolyses the potent vasoconstrictor angiotensin II to angiotensin (1-7). It is a consequence of this action that ACE2 participates in the renin-angiotensin system. However, ACE2 also hydrolyses dynorphin A (1-13), apelin-13 and des-Arg 9 bradykinin. The CMLS, Cell. Mol. Life Sci. 61 (2004) 
Introduction
Over 60 years have passed since the renin-angiotensin system (RAS) was initially described [1] . Since that time, the RAS has become one of the best-characterized hormonal systems, reflecting its central role in the control of blood pressure. Within the RAS, angiotensin II (Ang II) is considered the primary physiological product, and the basic pathway leading to Ang II formation has remained unchanged in theory. The RAS cascade is inaugurated with the hydrolysis of the precursor angiotensinogen to angiotensin I (Ang I) by the aspartic protease, renin. Ang I is, in turn, converted to Ang II principally by the zinc metallopeptidase angiotensin-converting enzyme (ACE), although in the heart the serine protease chymase also appears to play a role ( fig. 1) [2] . Throughout the past decade, the formation and function of other angiotensin fragments, such as Ang (1-7), Ang (1-9), Ang III [Ang (2-8)] and Ang IV [Ang (3-8)] have been investigated. In particular, the role of Ang (1-7) has been of greatest * Corresponding author.
impact, since this fragment mediates opposing effects to Ang II, thus providing a novel channel of regulation within the RAS [3] ( fig. 1 ). Ang (1-7) acts through its own specific G-protein-coupled receptor, Mas [4] . ACE has been identified as a fundamental regulator of the RAS in humans and is an important target in regulation of blood pressure homeostasis. Classical ACE inhibitors, such as captopril and lisinopril, have proven to be effective anti-hypertensive therapeutics [5] . In 2000, a human homologue of ACE was discovered independently by two groups using differing genomic-based strategies and was referred to as ACEH [6] or ACE2 [7] . The ability of ACE2 to produce Ang (1-7) via two alternative pathways, in concert with ACE ( fig. 1 ), has led to its increasing therapeutic relevance and interest. Most recently, ACE2 has been implicated in cardiac dysfunction, hypertension [8, 9] , heart failure and ventricular remodelling [10, 11] , diabetes [12] , Ang (1-7) regulation during pregnancy [13] and as a functional receptor to the coronavirus that cause severe acute respiratory syndrome (SARS) [14] . The foundation for future research into the biochemistry and physiological role of this enzyme has been provided both by the development of specific ACE2 in-Multi-author Review 2705 hibitors [15, 16] and the elucidation of crystal structures for ACE2 [17] , testicular ACE (tACE) [18] and its Drosophila orthologue, AnCE [19] .
Structure of the ACE2 gene
Orthologues of human ACE2 have been identified in both the rat and mouse genomes and display ~86 and 82% identity, respectively, to the nucleotide sequence of human ACE2. The human ACE2 gene consists of 18 exons, with the first 12 exons of ACE2 being of similar size to the first 11 exons of the ACE gene [6, 7] (fig. 2) . In ACE2 there is a union of exons 5 and 6, which jointly correspond to exon 5 of ACE (fig. 2) ; the zinc-binding motif (HEXXH) of ACE2 is located within exon 9, compared to exon 8 of the ACE gene. A significant difference between ACE2 and ACE is that only a single ACE2 protein species appears to be formed. The mammalian ACE gene gives rise to two isoforms, somatic ACE (sACE) with two catalytic domains (N-and C-domain) and tACE, which has only a single catalytic domain and resembles the C-domain of sACE ( fig. 2) . The initiation sites of the transcripts for sACE and tACE occur in different regions of the ACE gene and are under the control of alternate, tissue-specific promoters [20] . The regulatory elements for the ACE2 gene have thus far not been described.
The ACE2 gene maps to the X chromosome in humans (Xp22) [6, 7] , rodents (Xq32) [8] and mice (XF5) [21] . In three different rat models of either spontaneous or salt-induced hypertension, the rat gene was mapped to a defined quantitative trait locus (QTL) on the X chromosome. In these hypertensive rat models, a reduction in ACE2 gene and protein expression was observed, suggesting that ACE2 is a strong candidate for a hypertensive QTL on the X chromosome [8] . Furthermore, two single-nucleotide polymorphisms have been identified in the ACE2 locus and were associated with a number of cardiovascular endpoints in Caucasian subjects [22] . The strong association of the ACE2 gene with hypertension is further strengthened by the tissue-specific expression of the ACE2 messenger RNA (mRNA) at high levels as a single 4.3-kb transcript in kidney and heart [6, 7] . Immunohistochemical studies of heart sections have localised ACE2 to the endothelium of ventricular intramyocardial vessels and occasionally over the smooth muscle and adventitia of larger blood vessels. Surprisingly, no difference in immunoreactive staining was observed between sections of non-failing and failing hearts, although ACE2 was originally cloned from a human heart failure complementary DNA (cDNA) library [7] , and ACE2 activity is increased in human heart ventricles of idiopathic dilated cardiomyopathy patients [10] . In the kidney, ACE2 was observed on endothelium of intrarenal arteries Figure 1 . Schematic diagram of the renin-angiotensin system (RAS). In the classical RAS, angiotensin-converting enzyme (ACE) catalyses the production of angiotensin (Ang) II from Ang I. Ang II is a biologically active vasoconstrictor that interacts with angiotensin G-protein-coupled receptors AT1 and AT2. Ang (1-7), a metabolite of Ang I and Ang II, has opposing effects to Ang II which are mediated via interaction with the Mas [Ang (1-7)] receptor. ACE2 converts Ang II to Ang (1-7) with 370-fold greater catalytic efficiency than its conversion of Ang I to Ang (1-9). NEP, neprilysin; AP-N, aminopeptidase N; AP-A, aminopeptidase A. and the epithelia of proximal tubules [7] . As with other zinc metalloproteases, such as tACE [23] and neprilysin [24] , ACE2 is also highly expressed in testes [6, 7] , although ACE2 knockout male mice appear fertile [8] . Recently, a more extensive assessment of ACE2 expression using quantitative real-time polymerase chain reaction (PCR) and tissue immunohistochemistry has revealed an even higher level of ACE2 gene and protein expression in all regions of the gastrointestinal (G-I) tract, in addition to its high expression in the heart, kidney and testes [25, 26] .
The ACE2 protein
The open reading frame of human ACE2 encodes an 805-amino-acid polypeptide [6] . Hydropathy analysis of the ACE2 protein sequence reveals two hydrophobic regions, a potential 18-amino-acid signal peptide at the N-terminus and a 22-amino-acid hydrophobic region near the Cterminus. Like ACE, ACE2 is likely to be a type I integral membrane protein, anchored to the cell membrane via the hydrophobic region located towards the C-terminus of the protein. The N-terminal region of ACE2, which contains the active site, faces the extracellular space. ACE2 has been localised to the cell surface in stably transfected Chinese hamster ovary (CHO) cells by both immunofluorescence and cell surface biotinylation studies (F. J. Warner and Turner A. J. 2003, unpublished data). Thus, ACE2, like ACE, is an ectoenzyme, poised at the cell surface to hydrolyse circulating peptides.
Glycosylation
Human ACE2 has six potential N-glycosylation sites, as indicated by the presence of the Asn-X-Ser/Thr motif (at positions Asn 53 , Asn 90 , Asn 103 , Asn 322 , Asn 432 , Asn 546 ) in its primary structure [6, 17] . Complete deglycosylation of denatured soluble ACE2 with N-glycosidase F, which hydrolyses all classes of Asn-linked glycans, results in a shift in the migration of the polypeptide from 120 to ~85 kDa, the predicted M r for unglycosylated ACE2 [6] . Comparatively, sACE contains 17 N-glycosylation sites, of which 10 are located in the N-domain, the remaining 7 being found in both the C-domain of sACE and in tACE. In addition to N-linked glycans, tACE is also extensively O-glycosylated within the first 36 amino acids of the Nterminal sequence, although these O-linked sugars are not essential for expression or activity [27] . O-Linked glycosylation has not been reported for sACE or ACE2.
Whether the presence of all sugar moieties associated with ACE2 glycosylation is necessary for correct targeting and activity remains to be established. The contribution of five of the potential glycosylation sites for expression, processing and activity in human tACE and rabbit ACE has been investigated [28] [29] [30] in an effort to produce a minimally glycosylated form of tACE for crystallisation studies [18] . Glycosylation at either the first or third sites (from the N-terminus) is sufficient to produce a catalytically active form of human tACE [30] . Similarly, the first and second sites are essential for rabbit tACE [28] . Of the seven potential glycosylation sites of ACE2, the first putative site, Asn 53 , in humans is found to be conserved in rat ACE2, as well as in human, mouse and rabbit tACE, and Drosophila Ance and Acer, suggesting that this site is essential for maintaining activity. Overall, these studies of sACE and tACE [28] [29] [30] [31] [32] imply that carbohydrate processing has an essential role in the expression, maturation and proteolytic activity of membrane-bound and soluble ACE by influencing polypeptide folding and intracellular targeting and transport. Similar studies are required to reveal which of the potential glycosylation sites are important for the processing of ACE2.
Possible mechanisms of anchorage and solubilisation
Both sACE and tACE are solubilised from the membrane surface through the action of ACE secretase [33] , the precise identity of which is still unknown. Even so, it is thought to be a member of the adamalysin (ADAM) family of zinc metalloproteases [34] . Comparative inhibitor studies suggest that ACE secretase is related, although distinct from, the well-characterised, tumour necrosis factor-a convertase (TACE, ADAM 17) [35] [36] [37] . ACE2 also exists in both a membrane-bound and a soluble form [6] [7] [8] . In CHO cells stably expressing ACE2, an active form of ACE2 is secreted from cells into the medium [6] . These studies suggest that the soluble form of ACE2 is derived from the membrane-bound form via a post-translational proteolytic cleavage event similar to that occurring with ACE. The cleavage site for human tACE and sACE has been mapped to the Arg 1203 /Ser 1204 bond (sACE numbering), 24 amino acids proximal to the cell membrane, in vitro and in vivo [38, 39] . The exact sequences around the cleavage site or distance from the membrane do not appear to be direct determinants of secretase activity [40, 41] , but may be dependent on the conformational state of the juxta-membrane stalk region [42] . The juxtamembrane regions of human ACE and ACE2 display minimal sequence homology. Nevertheless, at least two potential (Arg-Ser and Arg-Leu) secretase cleavage sites exist within the juxtamembrane stalk region of ACE2. Whilst the formation of soluble ACE2 has been established in vitro [6, 7] , a soluble form of ACE2 has not yet been detected in vivo in human body fluids, although ACE2 has been detected in urine collected from rats [M. C. Chappell, 2003, unpublished data]. Until now, the majority of studies in rat and mouse models [8, 9] have thus far relied on an indirect means of measuring ACE2 activity in plasma through changes in levels of either Ang II or its metabolite Ang (1-7), by radioimmunoassay [43] . Future investigation into the mechanisms involved in the solubilisation of ACE2 and whether this secretory event is regulated will aid our understanding of the physiological relevance of ACE2 in modulating Ang I, Ang II and its other potential substrates both locally and systemically.
Catalytic properties of ACE2
ACE2 is a zinc metalloprotease that belongs to the gluzincin clan (MA) of metalloproteases, of which thermolysin is the archetypal member. Catalysis by members of this family occurs via a mechanism whereby zinc facilitates nucleophilic attack by a water molecule on the scissile carbonyl bond of the substrate. Rather than form a covalent intermediate, metalloproteases utilise co-ordination of a water molecule to a metal ion to form a noncovalent intermediate. Three other ligands co-ordinate the zinc ion and are conserved in all metalloproteases of the MA family ( fig. 3a) . In ACE2, the first two zinc coordinating ligands, His 374 and His 378 , are found within the consensus sequence, HEXXH, whereas the third zinc ligand, Glu 402 , lies 23 amino acids C-terminal to this motif. Corresponding residues are found in the two domains of ACE and tACE ( fig. 3a) [18, 20] . In ACE, an EXXXD motif contains the third zinc ligand (E) followed by an aspartyl residue. In ACE2, Glu 406 replaces this aspartyl residue, whose role in ACE is to position the first histidine zinc ligand ( fig. 3a) . Mutagenesis of Asp 991 to Glu in the C-domain of sACE reduces, but does not eliminate, the activity of wild-type ACE [44] . The role of Glu 406 in ACE2 remains to be explored. Based upon sequence alignment, ACE2 more closely resembles the N-domain of sACE with ~60% similarity and 41% identity to the overall protein sequence of sACE [6] . Although the juxtamembrane, transmembrane and cytoplasmic domains of ACE2 do not resemble sACE, they do share 48% identity with a 222-amino acid transmembrane glycoprotein, collectrin, which is derived from renal collecting ducts [45] (fig. 2) . ACE2 has been classified as member of the M2 family along with sACE, tACE and Drosophila Ance and Acer. However, unlike other CMLS, Cell. Mol. Life Sci. Vol. 61, 2004 Multi-author Review 2707 members of the M2 family, ACE2 is a carboxypeptidase rather than a peptidyl dipeptidase, being the first mammalian carboxypeptidase to be identified to contain the HEXXH motif rather than the typical carboxypeptidase A-like motif, HXXE(X) 123-132 H. In this sense, ACE2 more closely resembles the bacterial carboxypeptidases of the M32 family, Thermus aquaticus carboxypeptidase (TaqCP) [46] and Pyrococcus furiosus carboxypeptidase (PfuCP) [47] , which also utilize an HEXXH motif for zinc binding [48] (fig. 3a) . The high sequence homology between ACE2 and the bacterial carboxypeptidases is, however, only confined to the region surrounding the catalytic binding domains. Consequently, ACE2 has been separated from the M32 family carboxypeptidases when portrayed schematically in a cladogram based upon protein sequence alignment ( fig. 3b ). However, despite there being a lack of sequence homology, close similarities have been noted between the tertiary structures of ACE2 [17] tACE, [18] , PfuCP [47] and the neurotensin-degrading enzyme, neurolysin [49] , suggesting convergent structural evolution of these metalloproteases.
Substrate specificity
The recent elucidation of crystal structures for human ACE2 [17] and a previously described comparative model of the ACE2 active site, based upon the crystal structure of tACE [18, 50] , have identified key active site differences between ACE2 and tACE. Both studies indicate that the catalytic mechanism of ACE2 closely re- Multi-author Review 2709 sembles that of ACE. Differences in substrate specificity, however, suggest distinctive differences exist between the substrate binding subsites of ACE2 and tACE. ACE2 cleaves a single amino acid from the C-terminus of its substrates, whereas ACE functions as a peptidyl dipeptidase. The basis for this difference relates to the pocket (S2¢ subsite) and binding of the substrate C-terminus. In ACE2, the S2¢ subsite is smaller as a result of the R273 fi Q substitution and is only able to accommodate one amino acid instead of a second terminal peptide bond, as compared with that of tACE [17, 50] . The inhibitory action of ACE inhibitors, captopril and lisinopril, is based, in part, upon their ability to mimic the dipeptidyl C-terminal binding of ACE substrates [51] . This feature may be one factor that contributes to the ineffectiveness of captopril and lisinopril to inhibit the proteolytic activity of ACE2 [6] . A diverse range of peptides have been screened as potential physiological substrates for ACE2 [50, 52] . Around 12 peptides have been identified that are hydrolysed to a significant extent by ACE2 (table 1). ACE2 cleaves both Ang I and Ang II, although ACE2 has an almost 400-fold higher catalytic efficiency for hydrolysis of Ang II [52] . Ang I also inhibits ACE2 hydrolysis of fluorogenic substrate Mca-APK(Dnp)-OH weakly (K i = 2.2 mM) [14] . The majority of studies investigating a physiological role for ACE2 have concentrated on the ability of ACE2 to hydrolyse Ang II and its role in the RAS. However, ACE2 also hydrolyses the opioid peptide dynorphin A (1-13) and the hypotensive peptide apelin-13 with comparable kinetics to that of Ang II, as well as des-Arg 9 bradykinin, b-casomorphin and the growth hormone secretagogue ghrelin [52] . The ability of ACE2 to hydrolyse substrates other than Ang II suggests ACE2 may have a role in these other peptidergic systems. Alignment of the substrates hydrolysed by ACE2 reveals a potential consensus sequence, P 3 -X-P 1 fl X hydrophobic/basic , where the cleavage site occurs between the P 1 and a C-terminal hydrophobic/basic residue [50] . The vast majority of peptides efficiently cleaved by ACE2 possess a proline at the penultimate position (P 1 ) of the peptide and a phenylalanine at the C-terminus. However, a basic residue can be substituted at the C-terminus, as observed in neurotensin (1-8), neurotensin (1-11) and ghrelin (table 1) [50, 52] . The topology of the S1 subsite, in particular residue Y510, appears to be a determining factor in limiting the size of the residue found at the substrate P 1 position. Substrates with medium-sized amino acids such The sequence of each peptide is depicted using single-letter codes for each amino acid. An arrow indicates the site of hydrolysis. C, complete hydrolysis; P, partial hydrolysis; N, no hydrolysis all indicate the degree to which peptide substrates were hydrolysed. N.D., not determined.
as proline or leucine, but not bulky residues like tyrosine or phenylalanine, at the P 1 position are cleaved [17] . The presence of a proline at P 3 , but not P 2 , may also be a determinant for ACE2 activity [50] . For instance, both Ang I and dynorphin A (1-13) which contain a proline at the P 3 position are cleaved by ACE2, whereas a proline at the P 2 position, as observed in Ang (1-9) and bradykinin, prevents hydrolysis by ACE2. The exception to this is neurotensin (1-13) , which despite having a proline in the P 3 position, is not a substrate for ACE2 (table 1) . Further clarification of the rules governing ACE2 hydrolysis is required.
pH and anion activation
Current studies [50, 52, 53] have established the dependence of ACE2 on pH and monovalent anions for catalytic activity. Anion activation of Ang I hydrolysis by ACE was first recognised by Skeggs and co-workers in 1954 [54] . The dependence of ACE on chloride ions is both substrate- [55] and domain-specific [56] . Both ACE and ACE2 exhibit a preference for Cl -over other monovalent ions, F -and Br - [52, 57] . The molecular mechanism for anion activation is yet to be fully understood, although it has been proposed that chloride ions may induce a slight change in the conformation of the active site that facilitates binding [58] . The crystal structure for lisinopril-complexed tACE has revealed two concealed chloride ions [18] . Four ligands, Arg 489 , Arg 186 , Trp 485 and water bind the first chloride ion (Cl1). The ligands, Tyr 224 , Arg 522 and a water molecule bind the second chloride ion (Cl2), which is located closer to the co-ordinated zinc ion [18] . The C-domain ACE residue Arg 1098 (equivalent to Arg 522 in tACE) has been identified as a crucial residue for Cl -activation of sACE activity [59] . Both Tyr 244 and Arg 522 are conserved in human ACE2 (Tyr 207 and Arg 514 ), in addition to all known ACE sequences [59] , implying that these conserved residues may also be involved in mediating the Cl -effect observed for ACE2 and other related ACEs. However, the native crystal structure of the ACE2 ectodomain shows only a single bound chloride ion, instead of two as observed in the lisinopril-complexed tACE [17] . The location of this single chloride ion in the native ACE2 structure is almost identical to the position of the first chloride ion (Cl1) in the lisinopril-complexed tACE [17, 18] . Since no native crystal structure for tACE has been solved [18] and the resolution of the crystal structure of ACE2 complexed with MLN4760 (ACE2 inhibitor) was not high enough to differentiate water from chloride ions [17] , it remains unknown if the second chloride ion (Cl2) in lisinopril-complexed tACE is unique to the inhibitor bound state. Future site-directed mutagenesis studies of the potential residues involved in chloride binding will give a greater understanding of the mechanisms underlying anion activation. [50] . The control of ACE2 activity through pH and anion activation presents the question of its physiological relevance. Both pH and chloride ion concentrations are, for the most part, relatively constant in blood plasma, to which ACE and ACE2 are theoretically exposed. Under physiological conditions, pH 7.4 and 100 mM [Cl -], and based upon the data presented by Guy and co-workers [50] , ACE2 would only exhibit ~15% of its maximal activity for Ang I, but be ~90% active towards Ang II. Hence, it may be that anion activation serves to regulate substrate specificity, particularly in organs such as the kidney where chloride ion concentrations fluctuate greatly.
Inhibitor design and studies
The first generation of selective inhibitors for ACE2 have been designed and synthesised (table 1) [15, 16] . A series of non-peptide compounds were constructed based upon the ACE2 substrate consensus P-X(1-3)-P 1 -fl-X hydrophobic and the requirement of a centrally located carboxylate to co-ordinate with the zinc ion [15] . This lead resulted in the synthesis of an inhibitor (MLN-4760, table 1) possessing sub-nanomolar affinity (IC 50 , 50% inhibitor concentration 0.44 nM) for ACE2 and 220,000-and 22,000-fold less affinity for human tACE and bovine carboxypeptidase A, respectively [15] . Using an alternative strategy, potent ACE2 peptide inhibitors have been identified through screening of constrained peptide libraries [16] . The most potent inhibitor, DX600, a 26-amino acid N-terminal acetylated and Cterminal amidated peptide, displays a K i of 2.8 nM using Ang I as a substrate. DX600 exhibited a combination of both competitive and non-competitive inhibition. Intravenous bolus injection of DX512 (K i , 139 nM), an analogue of DX600, in conscious spontaneously hypertensive rats (SHR) produced a dose-dependent depressor response characterised by a decreased mean arterial pressure and accompanied by transient tachycardia [16] . These findings are in contrast to the hypothesis that ACE2 is linked to systemic arterial pressure [60] . This hypothesis is supported by studies in ACE2 knockout mice where ablation of ACE2 either did not have a direct effect on blood pressure or increased systolic blood pressure [8, 9] . Furthermore, ACE2 mRNA and protein expression levels are reduced in SHR compared with control Wistar Kyoto rats [8] . There are two possible explanations for these conflicting results. First, Ang II may not be the sole physiological substrate involved in mediating the effects of ACE2 on blood pressure. Apelin-13 (k cat /K m , 2.0 ¥ 10 6 M -1 s -1 ) is cleaved by ACE2 with kinetics similar to that of Ang II (k cat /K m , 1.8 ¥ 10 6 M -1 s -1 ), and apelin-36 is also a substrate [52] . Both peptides also produce hypotensive systemic effects [61, 62] that may be accentuated in the absence of ACE2. Second, the inconsistencies observed among these studies may originate from the fundamental differences that exist between an animal which has never produced a protein and may develop compensatory mechanisms and an animal in which the same protein is inhibited after birth. Nevertheless, with the recent development of inhibitors these discrepancies can now be addressed, as well as promote new studies of ACE2 in normal physiology and in disease.
Conclusions and future perspectives
In a remarkably short space of time, much knowledge has accumulated on the structure, enzymology and physiological functions of ACE2, but much still remains to be elucidated. The counterbalancing roles of ACE and ACE2 in the RAS are gaining credence, but other metabolites, for example apelin, may be physiologically relevant substrates. ACE2 has been implicated in a number of disease conditions including hypertension, diabetes and cardiac function. Most recently, its identity as the SARS virus receptor opens new avenues for ACE2 research particularly in relation to the nature of the interactions between the viral spike glycoprotein and ACE2. More clinical studies are required to validate disease models, and for this purpose, generally available ACE2 inhibitors are of fundamental importance. The recent structural solutions of both ACE and ACE2 should facilitate further design of potent and selective ACE2 inhibitors. Finally, in this rapidly developing field, there may be yet further surprises that this new member of the ACE gene family has to provide.
